Search General Info
Search Education
Search Partnering Companies
photo
Speaker

Andrew Schwab

FOUNDER AND MANAGING PARTNER, 5AM VENTURES
San Francisco, California, United States
Andy Schwab is a Founder and Managing Partner of 5AM Ventures. Prior to founding 5AM in 2002, Mr. Schwab was a Principal at Bay City Capital where he was involved with companies such as Cubist, PTC Therapeutics, Symyx and Syrrx. Previously Mr. Schwab was Vice President of Business Development at Digital Gene Technologies and a Vice President in the life science investment banking group of Montgomery Securities. At 5AM, he has led the firm’s investments in and served on the Boards of Bird Rock Bio, Blue Light Therapeutics, Cleave Therapeutics, DVS (acquired by Fluidigm), Escient, Flexion Therapeutics (NASDAQ: FLXN), Ikaria (acquired by Mallinckrodt and spun-out Bellerophon (NASDAQ: BLPH), Ilypsa (acquired by Amgen), Miikana Therapeutics (acquired by EntreMed), Novome, Panomics (acquired by Affymetrix), Pear Therapeutics, Precision NanoSystems, Purigen, Synosia (acquired by Biotie), TMRW and Viveve (NASDAQ: VIVE). Mr. Schwab also serves on the Boards of Trustees of the California Academy of Sciences, Davidson College and the National Venture Capital Association (NVCA). Mr. Schwab received a B.S. with Honors in Genetics & Ethics from Davidson College and was a member of its 1992 Final Four soccer team. Mr. Schwab is based in the San Francisco, CA office.
Speaking In
12:00 PM - 12:45 PM (EDT)
Thursday, June 17

BIO, in partnership with Coqual, is launching the second-annual Measuring Diversity and…